A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

BACKGROUND: Stimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial of cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist) and nivolumab. Our current purpose was to study the activity and cellular effects of this t...

Descripción completa

Detalles Bibliográficos
Autores principales: Djureinovic, Dijana, Weiss, Sarah A., Krykbaeva, Irina, Qu, Rihao, Vathiotis, Ioannis, Moutafi, Myrto, Zhang, Lin, Perdigoto, Ana L., Wei, Wei, Anderson, Gail, Damsky, William, Hurwitz, Michael, Johnson, Barbara, Schoenfeld, David, Mahajan, Amit, Hsu, Frank, Miller-Jensen, Kathryn, Kluger, Yuval, Sznol, Mario, Kaech, Susan M., Bosenberg, Marcus, Jilaveanu, Lucia B., Kluger, Harriet M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644655/
https://www.ncbi.nlm.nih.gov/pubmed/37964379
http://dx.doi.org/10.1186/s12943-023-01884-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644655/
https://www.ncbi.nlm.nih.gov/pubmed/37964379
http://dx.doi.org/10.1186/s12943-023-01884-x

Ejemplares similares